Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.

Huzarski T, Górecka-Szyld B, Huzarska J, Psut-Muszyńska G, Wilk G, Sibilski R, Cybulski C, Kozak-Klonowska B, Siołek M, Kilar E, Czudowska D, Janiszewska H, Godlewski D, Mackiewicz A, Jarkiewicz-Tretyn J, Szabo-Moskal J, Gronwald J, Lubiński J, Narod SA; Polish Hereditary Breast Cancer Study Group.

Hered Cancer Clin Pract. 2017 Mar 1;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017.

2.

Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.

Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP 3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G; ACRIN 6666 Investigators.

JAMA. 2012 Apr 4;307(13):1394-404. doi: 10.1001/jama.2012.388.

3.

Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.

Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, Tombach B, Leutner C, Rieber-Brambs A, Nordhoff D, Heindel W, Reiser M, Schild HH.

J Clin Oncol. 2010 Mar 20;28(9):1450-7. doi: 10.1200/JCO.2009.23.0839. Epub 2010 Feb 22.

PMID:
20177029
4.

Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.

Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara M, Samuels TH, Murphy JP, Murphy JM, Narod SA.

J Clin Oncol. 2001 Aug 1;19(15):3524-31.

PMID:
11481359
5.

Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.

Riedl CC, Ponhold L, Flöry D, Weber M, Kroiss R, Wagner T, Fuchsjäger M, Helbich TH.

Clin Cancer Res. 2007 Oct 15;13(20):6144-52.

6.

Multimodality screening of high-risk women: a prospective cohort study.

Weinstein SP, Localio AR, Conant EF, Rosen M, Thomas KM, Schnall MD.

J Clin Oncol. 2009 Dec 20;27(36):6124-8. doi: 10.1200/JCO.2009.24.4277. Epub 2009 Nov 2.

7.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
8.

Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.

Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.

9.

Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.

Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH.

J Clin Oncol. 2005 Nov 20;23(33):8469-76.

PMID:
16293877
10.

Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results.

Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, Vergnaghi D, Federico M, Cortesi L, Corcione S, Morassut S, Di Maggio C, Cilotti A, Martincich L, Calabrese M, Zuiani C, Preda L, Bonanni B, Carbonaro LA, Contegiacomo A, Panizza P, Di Cesare E, Savarese A, Crecco M, Turchetti D, Tonutti M, Belli P, Maschio AD; High Breast Cancer Risk Italian 1 (HIBCRIT-1) Study.

Invest Radiol. 2011 Feb;46(2):94-105. doi: 10.1097/RLI.0b013e3181f3fcdf.

PMID:
21139507
11.

Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.

Warner E, Causer PA, Wong JW, Wright FC, Jong RA, Hill KA, Messner SJ, Yaffe MJ, Narod SA, Plewes DB.

Breast J. 2011 Jan-Feb;17(1):9-17. doi: 10.1111/j.1524-4741.2010.01018.x.

PMID:
21251121
13.

Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.

Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA; International Breast MRI Consortium Working Group.

Cancer. 2005 May 1;103(9):1898-905.

14.

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.

Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.

Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.

PMID:
31221620
15.

Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.

Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.

PMID:
23940285
16.

Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.

Obdeijn IM, Winter-Warnars GA, Mann RM, Hooning MJ, Hunink MG, Tilanus-Linthorst MM.

Breast Cancer Res Treat. 2014 Apr;144(3):577-82. doi: 10.1007/s10549-014-2888-8. Epub 2014 Feb 25.

PMID:
24567197
17.

Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.

Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM.

BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440.

18.

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG; Magnetic Resonance Imaging Screening Study Group.

N Engl J Med. 2004 Jul 29;351(5):427-37.

19.

Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer.

Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S.

Radiology. 2017 May;283(2):361-370. doi: 10.1148/radiol.2016161444. Epub 2017 Feb 21.

PMID:
28221097
20.

Responding to the challenges of breast cancer in egypt and other arab countries.

El Saghir NS.

J Egypt Natl Canc Inst. 2008 Dec;20(4):309-12.

Supplemental Content

Support Center